Akeso's Ivonescimab demonstrates superior overall survival compared to Pembrolizumab in PD-L1-positive NSCLC
Executive summary: Akeso, Inc. presented positive overall survival results from its HARMONi-2 Phase III trial at the 2026 World Conference on Lung Cancer. The study shows Ivonescimab offers a significant benefit over the current standard-of-care, Pembrolizumab, in first-line PD-L1-positive NSCLC treatment.
Who is involved: Akeso, Inc. (manufacturer of Ivonescimab).
Likely next: Regulatory filings for expanded indications and potential shifts in global treatment guidelines for NSCLC.
Akeso’s presentation of the HARMONi-2 trial at WCLC 2026 showed that Ivonescimab achieved a statistically significant overall survival advantage over pembrolizumab in patients with PD-L1‑positive non‑small cell lung cancer. The data, while still preliminary in the public domain, add to the growing body of evidence that bispecific antibodies can outperform existing PD‑1 monotherapy in the first‑line setting. This outcome directly challenges pembrolizumab’s current role as a standard of care for this patient subgroup and may prompt clinicians to reassess treatment algorithms pending further validation. In parallel, the approval of Ivonescimab combined with chemotherapy for first‑line squamous NSCLC expands the drug’s indication beyond the PD‑1‑positive population addressed in HARMONi‑2. Such a label could increase Ivonescimab’s market reach and create competitive pressure on both pembrolizumab and chemotherapy‑only regimens. Ongoing exploration of Ivonescimab in combination pipelines—such as the Phase II trial pairing it with the TROP2/Nectin‑4 bispecific ADC AK146D1—suggests that Akeso is pursuing synergistic strategies to deepen its presence in NSCLC. Near‑term developments to watch include additional readouts from HARMONi‑2, potential regulatory submissions for broader indications, and results from the combination studies that could shape future therapeutic pathways.
What's next — scenarios
Base Case: Broad Regulatory Approval (60%)
Ivonescimab replaces Pembrolizumab as the primary first-line therapy in many markets.
- FDA/NMPA approval of HARMONi-2 data
- Integration into clinical practice guidelines
Upside: Rapid Global Adoption (25%)
Accelerated market share capture and significant revenue increase for Akeso.
- Confirmation of safety profile in broader populations
- Favorable reimbursement negotiations
Downside: Regulatory Delay (15%)
Market entry postponed due to requests for additional subgroup analyses.
- FDA request for further safety data
- Discrepancies in regional efficacy data
What to watch
- Regulatory decisions from NMPA and FDA regarding the HARMONi-2 results
- Next quarterly earnings reports from Akeso, Inc. (9926.HK)
- Updating of oncological treatment guidelines by major medical associations
Timeline
- — Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 Presented at WCLC 2026 (PR Newswire)
- — Ivonescimab Plus Chemotherapy Approved for First-Line Squamous NSCLC (PR Newswire)
Analysis — what this means
Likely next events
- Regulatory review of HARMONi-2 data by major health authorities
- Potential expanded clinical trials for Ivonescimab combinations
Sectors affected
- Biotechnology
- Oncology Pharmaceuticals
- Healthcare Services
Regulatory implications
- Potential update to NMPA approval status for Ivonescimab in NSCLC
Historical parallels
- Pembrolizumab market dominance since 2014
Key entities
Sources
- Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 Presented at WCLC 2026 — PR Newswire
- Ivonescimab Plus Chemotherapy Approved for First-Line Squamous NSCLC — PR Newswire
Related cases
- PTK7 emerges as stable ADC target in EGFR wild-type NSCLC, boosting Whitehawk's HWK-007 prospects
- Sacituzumab govitecan plus pembrolizumab fails to meet primary endpoints in first‑line PD‑L1‑high metastatic NSCLC, dealing a setback to the ADC‑immunotherapy combo approach
- SystImmune’s Phase 1 data for Iza-bren show promising activity in EGFR‑mutated lung cancer, backing a 2.5 mg/kg dose for Phase 3
- Akeso initiates Phase II trial of a novel TROP2/Nectin-4 bispecific ADC combined with Ivonescimab, advancing its oncology pipeline in NSCLC
- Kelun-Biotech’s Phase III trial shows its antibody-drug conjugate plus pembrolizumab beats chemo‑immunotherapy in PD‑L1‑negative NSCLC, potentially reshaping first‑line lung‑cancer treatment